Indication
Fibrodysplasia ossificans progressiva
Fibrodysplasia ossificans progressiva is an ultra-rare, severely disabling autosomal dominant genetic disorder of the connective and musculoskeletal systems. Read more about Fibrodysplasia ossificans progressiva
3 drugs 3 manufacturers
Drugs that treat it
Common Fibrodysplasia ossificans progressiva therapies.
PASATRU (garetosmab-grts)
ATEBRIOZ (zilurgisertib fumarate)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonFibrodysplasia ossificans progressiva is an ultra-rare, severely disabling autosomal dominant genetic disorder of the connective and musculoskeletal systems.
Most commonly caused by activating mutations in the *ACVR1* gene, the condition leads to dysregulated bone morphogenetic protein signaling that drives progressive, endochondral heterotopic ossification within skeletal muscle, tendons, ligaments, and fascia.
Clinically, affected individuals typically present at birth with characteristic congenital malformations of the great toes, followed in early childhood by episodic, painful soft-tissue flare-ups often triggered by minor trauma, intramuscular injections, or viral illness.
Over time, cumulative extraskeletal bone formation bridges joints across the axial and appendicular skeleton, culminating in progressive immobility, ankylosis, and life-threatening thoracic insufficiency.
- nih.gov
Fibrodysplasia ossificans progressiva is an ultra-rare, severely disabling autosomal dominant genetic disorder of the connective and musculoskeletal systems Most commonly caused by activating mutations in the *ACVR1* gene, the condition leads to dysregulated bone morphogenetic protein signaling that drives progressive, endochondral heterotopic ossification within skeletal muscle, tendons, ligaments, and fascia Over time, cumulative extraskeletal bone formation bridges joints across the axial and...
- rarediseases.org
Fibrodysplasia ossificans progressiva is an ultra-rare, severely disabling autosomal dominant genetic disorder of the connective and musculoskeletal systems Most commonly caused by activating mutations in the *ACVR1* gene, the condition leads to dysregulated bone morphogenetic protein signaling that drives progressive, endochondral heterotopic ossification within skeletal muscle, tendons, ligaments, and fascia
- nih.gov
Fibrodysplasia ossificans progressiva is an ultra-rare, severely disabling autosomal dominant genetic disorder of the connective and musculoskeletal systems Most commonly caused by activating mutations in the *ACVR1* gene, the condition leads to dysregulated bone morphogenetic protein signaling that drives progressive, endochondral heterotopic ossification within skeletal muscle, tendons, ligaments, and fascia Clinically, affected individuals typically present at birth with characteristic congen...
- biologists.com
Most commonly caused by activating mutations in the *ACVR1* gene, the condition leads to dysregulated bone morphogenetic protein signaling that drives progressive, endochondral heterotopic ossification within skeletal muscle, tendons, ligaments, and fascia
- nih.gov
Clinically, affected individuals typically present at birth with characteristic congenital malformations of the great toes, followed in early childhood by episodic, painful soft-tissue flare-ups often triggered by minor trauma, intramuscular injections, or viral illness
- nih.gov
Clinically, affected individuals typically present at birth with characteristic congenital malformations of the great toes, followed in early childhood by episodic, painful soft-tissue flare-ups often triggered by minor trauma, intramuscular injections, or viral illness Over time, cumulative extraskeletal bone formation bridges joints across the axial and appendicular skeleton, culminating in progressive immobility, ankylosis, and life-threatening thoracic insufficiency
Personalize your experience
Follow Fibrodysplasia ossificans progressiva and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.